Skip to main content

SKIN CANCER HITS GREAT BARRIER REEF FISH

Australia’s sunny climate has been linked to high rates of skin cancer in humans but it now seems fish could also be susceptible.
Image result for GREAT BARRIER REEF FISH
Melanomas have been detected in wild fish populations for the first time in species on the world heritage-listed Great Barrier Reef.
The most likely culprit is ultra-violet radiation, says lead researcher Michael Sweet from the UK’s Newcastle University.
The university and the Australian Institute of Marine Science examined 136 coral trout caught at Heron Island and One Tree Island, in the southern area of the Great Barrier Reef Marine Park, between August 2010 and February 2012.
About 15 percent of the fish captured had dark lesions on the surface of the skin but were otherwise healthy.
The lesions were characteristic of melanomas created in laboratories on the fish species Xiphophorus, the research found.
The study, published in the journal PLoS One, said the sampled fish were caught in a protected marine park area with no evidence of pollution, and therefore the likelihood that the cancers were caused by carcinogenic pollutants was low.
“Further work needs to be carried out to establish the exact cause of cancer but having eliminated other likely factors such as microbial pathogens and marine pollution, UV radiation appears to be the most likely cause,” Dr. Sweet said.
Previous studies have shown UV radiation can have detrimental effects on marine and freshwater organisms and can penetrate as deep as 60 meters, the researchers said.
The coral trout in this study were all captured in less than 20 meters of water.
However, the high levels of melanoma in the population could also be linked to a genetic defect, said Australian Institute of Marine Science research fellow, Michelle Heupel.
She said it could be a combination of UV radiation, genetics, and the southern Great Barrier Reef location where coral trout live at their temperature limit, which could compromise their immune systems.
Dr. Huepel said commercial fishermen had observed the dark lesions on coral trout for many years, so the phenomenon was not a new one.
However, it was Dr. Huepel who raised the alarm and sent samples to Dr. Sweet for analysis.
She said coral trout can vary in color and therefore the brown and black spots may not have sparked curiosity before.
The study did not find any fish with advanced cancer. The authors suggesting those fish would be less active and feeding less, and therefore would not have been caught.
More work would need to be done to examine how the disease spreads and whether it is benign or malignant.
Coral trout are an iconic and commercially important species, supporting a high-value fishing industry on the reef.
Dr. Huepel said understanding the causes of the disease was important to the conservation and management of reefs.

Comments

Post a Comment

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...
Post a Comment
Read more

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...
Post a Comment
Read more

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...
Post a Comment
Read more